MMMark Messak

Mark Messak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark Messak has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Is It Safe to Stop? Predictors and Outcomes of Treatment Discontinuation in Multiple Sclerosis: A Systematic Review and Meta-Analysis

    by Haneen Sabet, Moaz Elsayed Abouelmagd, Mark Messak, Mohamed Ahmed Zanaty, Dalia Kamal Ewis, Hamdy A. Makhlouf, Obai Yousef, Abdullah Almarfadi, Omar Shaker, Abdelrahman Shata, et al.

  • Contributors

    by Abdallah Abbas, Celine Abboud, Ashrakt H. Abdelhamid, Dina Essam Abo-Elnour, Moaz Elsayed Abouelmagd, Esther Abosede Adewumi, Lila Agbaria, Mohamed Abdelsattar Ahmed, Md Anzar Alam, Gideon S. Alex, et al.

  • Repurposing existing drugs for Parkinson's disease management

    by Moaz Elsayed Abouelmagd, Mark Messak, Ahmed Farid Gadelmawla, Mrinmoy Kundu

  • Open Access

    Peripheral nerve stimulation for essential tremor: a GRADE-assessed systematic review and meta-analysis

    by Mark Messak, Yusof Mohamed Omar, Nada Mosad, Omar Ahmed, Hamdy A. Makhlouf

    Essential tremor (ET) is a common movement disorder; its management remains challenging despite the availability of multiple treatment options. Pharmacological therapies are often limited in efficacy and tolerability, while surgical options, although effective, are invasive and expensive. Peripheral nerve stimulation (PNS) has emerged as a non-invasive neuromodulation approach. However, different stimulation protocols, small samples, and inconsistent outcome reporting preclude firm conclusions. Therefore, we performed a systematic review and meta-analysis to evaluate the efficacy and safety of PNS for ET. A literature search was conducted through PubMed, Scopus, Web of Science, and Cochrane CENTRAL databases till January 2026. The primary outcome was the change in tremor intensity, as measured by the TETRAS Performance Scale (TETRAS-PS). Secondary outcomes included functional disability, assessed by the Bain and Findley Activities of Daily Living (BF-ADL) scale, clinical improvement assessed using the clinical global impression – improvement (CGI-I) scale, as well as safety outcomes. Quality assessment was performed using the Risk of Bias-2 (RoB-2) and the NIH single-arm tools. Certainty of evidence was assessed using GRADE approach. A meta-analysis was performed, calculating the mean difference (MD) with 95% confidence intervals (CIs) using Review Manager 5.4.1. Twelve studies, involving 914 participants, met the inclusion criteria, including four RCTs. Our analysis of RCTs demonstrated that active PNS produced a statistically significant reduction in tremor intensity (TETRAS-PS; MD=-0.92, 95%CI [-1.63 to -0.21], P = 0.01, I2 = 0) and an improvement in functional outcomes (BF-ADL; MD=-1.90, 95%CI [-2.97 to -0.83], p = 0.0005, I2 = 0). Benefits were observed immediately and persisted for up to three months in longitudinal studies. Adverse events were generally mild and limited mainly to transient skin irritation; no device-related serious adverse events were reported. PNS was associated with short-term reduction in tremor severity and functional impairment in patients with ET, with an overall acceptable safety profile, suggesting that it may serve as a middle ground option between pharmacotherapy and invasive neurosurgical approaches. However, further larger and longer randomized trials with refined sham controls are needed to confirm its efficacy, durability, and optimize stimulation strategies. CRD420261282826.

  • Bright light therapy for depression and excessive daytime sleepiness in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials with dose-response meta-regression

    by Mark Messak, Ahmed Abdelmageed, Youssef A. Khattab, Youssef Mandour, Omar Shaker, Ahmed Negida

    Non-motor symptoms, including depression and excessive daytime sleepiness (EDS), reduce quality of life in Parkinson's disease (PD). Pharmacological treatments may cause side-effects, highlighting the need for non-pharmacological approaches. We conducted an updated meta-analysis with linear and non-linear dose-response meta-regression to evaluate bright light therapy (BLT) on depression and EDS in PD. PubMed, Scopus, and WOS were systematically searched through September 2025. Risk of bias was assessed using RoB-2 and NIH single-arm tools. Mean difference (MD) or standardized mean difference (SMD) with 95%confidence intervals (CI) were pooled using fixed-effects models. Linear and non-linear dose-response meta-regressions were performed. Eight studies were identified, six included in meta-analysis. For EDS, five studies (n = 159) showed no significant effect of BLT (MD =-1.14, 95%CI [-2.43, 0.15], p = 0.083, I2 = 0%), with no linear (p = 0.78) or non-linear (p = 0.97) dose-response relationship. For depression, five studies (n = 194) also showed no significant effect (SMD =-0.13, 95%CI [-0.41, 0.16], p = 0.38, I2 = 0%), without linear (p = 0.82) or non-linear (p = 0.85) associations. Sensitivity analyses were consistent. BLT was not associated with significant improvement in depression or EDS in PD, and no dose-response relationship was identified. Given methodological limitations, BLT cannot currently be recommended for clinical use. Future standardized dose-finding trials stratified by disease stage and retinal/ipRGC integrity are needed.

  • Therapeutic effects of cannabinoids on Parkinson’s disease: an updated systematic review and meta-analysis of randomized controlled trials

    by Mark Messak, Ahmed Abdelmageed, Ahmed Noureldeen Abbas, Youssef Mandour, Ahmed Talkhan, Mahmoud Fadel Eltohami, Dua’A Kanaan, Fawaz K. Alfahmi, Habiba Tariq Saeed, Lara Hamzeh Hamzeh, et al.

    Current treatments for Parkinson's disease (PD) are primarily symptomatic and may lead to motor fluctuations and levodopa-induced dyskinesia over time, highlighting the need to repurpose other medications. Cannabinoids have gained attention as potential repurposed treatments. This systematic review and meta-analysis evaluated their efficacy in PD while addressing limitations of previous reviews, including low statistical power and inclusion of cannabinoid antagonists in pooled analyses. A literature search was conducted through PubMed, Scopus, and Web of Science, identifying randomized controlled trials (RCTs) evaluating the use of cannabinoids in PD. Quality assessment was done via RoB-2. A random-effects meta-analysis was performed using the meta and metafor packages in R, with mean differences (MD) or standardized mean differences (SMD; Hedges' g) reported with 95% confidence interval (CI). A sensitivity analysis was carried out to assess the robustness of our findings. In crossover trials, effect sizes and standard errors were extrapolated from the reported CIs, considering the paired design. Eleven RCTs were identified, six of which were eligible for meta-analysis due to the absence of poolable outcomes in the remainder. Cannabinoids did not significantly improve PD severity (SMD = 0.16, 95% CI[-0.13 to 0.44], p = 0.27, I²=0%), motor examination (SMD=-0.08, 95% CI[-0.35 to 0.20], p = 0.57, I²=0%), motor experiences of daily living (SMD=-0.08, 95% CI[-0.49 to 0.33], p = 0.71, I²=0%), non-motor symptoms (SMD= -0.03, 95% CI[-0.72 to 0.67], p = 0.94, I²= 64.3%). Sensitivity analysis excluding Peball et al. showed that the pooled estimate of non-motor symptoms was largely driven by nabilone (SMD = 0.34, 95%CI [-0.19 to 0.88], p = 0.21, I²=0%), suggesting a drug-specific benefit signal. Cannabinoids have not shown significant benefit in PD; however, our findings should be interpreted with caution. The nabilone benefit signal for non-motor symptoms represents a distinct question warranting dedicated trials. Future studies should use standardized, pharmacologically stratified protocols.


  • Top Cited Papers
    Open Access

    The impostor phenomenon construct in medical education: a meta-analysis of its prevalence and a critical appraisal of its measurement

    by Yusof Mohamed Omar, Youssef A. Khattab, Ahmed Abdelmageed, Mark Messak, Youssef Mandour, Abdullah Emad Shabeeb, Abdulrahman M. Zakaria, Moaz Elsayed Abouelmagd

    Impostor phenomenon (IP) is widely cited as a significant challenge in medical education, yet its conceptual and methodological foundations are unstable, hindering a clear understanding of its true scope and impact. Thus, this systematic review and meta-analysis aimed to first establish a pooled prevalence of IP among medical students, and second, to critically appraise the measurement tools and definitions used in the literature. We systematically searched PubMed, Scopus, Web of Science, and CINAHL through July 2025 for all studies quantitatively assessing IP prevalence in medical students. Using a random-effects model, we analyzed data from 34 studies, including 9,550 participants. The overall pooled prevalence of IP was 49% (95% CI [0.43–0.54]), but this figure is complicated by extreme heterogeneity across studies (I 2 =95.6%, P < 0.001) despite multiple sensitivity analyses. Subgroup analyses revealed significant prevalence differences by gender (females 51% vs. males 40%; P = 0.021), geographic region ( P < 0.001), and the measurement tool used ( P < 0.001). The qualitative synthesis suggested associations between IP and negative mental health outcomes, including anxiety, depression, and burnout. Nevertheless, the variance driven by different measurement tools suggests that researchers may not be consistently measuring the same construct. The reliance on unvalidated cutoffs further weakens the validity of prevalence estimates. We conclude that while IP is clearly a prevalent concern, the construct’s weak theoretical grounding and inconsistent measurement impede meaningful progress. Advancing this area of medical education research requires a foundational shift toward conceptual clarity and methodological rigor.


  • Open Access

    Efficacy and safety of GLP-1 agonists in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials

    by Mark Messak, Ahmed Abdelmageed, Abdelrahman A. Senbel, Youssef A. Khattab, Youssef Mandour, Omar Shaker, Ahmed Hamed Rehan, Samir Oransa, Mohamed Nasr, Abdullah Emad Shabeeb, et al.

    Recent trends suggest exploring the repurposing of different drugs for Parkinson’s disease patients (PD). One of these drugs is Glucagon-like peptide-1 (GLP-1), a medication used to treat type 2 diabetes mellitus. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of different forms of GLP-1 agonists on motor and non-motor functions of PD patients during ON-medication and OFF-medication states. A literature search was conducted through PubMed, Scopus, Web of Science, OVID, Cochrane Central, and Google Scholar using relevant keywords. Quality assessment was performed using the Risk of Bias-2 (RoB-2) domains. Statistical analysis included calculating the mean difference (MD) and the corresponding 95% confidence intervals (CIs) using Review Manager 5.4.1. Four randomized controlled trials (RCTs) testing three different forms of GLP-1 agonists with a total of 514 patients were included in the study. GLP-1 agonists significantly improved motor function during the OFF-medication state (MD = − 3.29, 95% CI [− 5.17 to − 1.42], P = 0.0006). It does not show improvement in quality of life assessed by PDQ-39 (MD = − 0.54, 95% CI [− 2.07 to 0.99], P = 0.49). None of the adverse effects stated in the RCTs were higher in the GLP-1 agonists group except for nausea (RR = 1.98, P = 0.0008), vomiting (RR = 6.65, P = 0.0008), constipation (RR = 1.45, P = 0.01), and weight loss (RR = 2.11, P = 0.03). This systematic review and meta-analysis provide evidence that GLP-1 agonists could improve the motor function of PD patients. However, safety is still of concern. Further high-quality studies with standardized protocols and larger sample sizes are needed to confirm our findings.